Literature DB >> 9716013

Characterization of a unique factor-independent variant derived from human factor-dependent TF-1 cells: a transformed event.

X Hu1, L C Moscinski, B J Hill, Q Chen, J Wu, A B Fisher, K S Zuckerman.   

Abstract

A factor-independent variant (TF-1a) has been isolated from the factor-dependent TF-1 cell line. The subline has been grown continuously in culture for > 1.5 years without added cytokines. The cells retain the ability to respond to multicytokines, with a different response pattern from its parental cell line. The TF-1 cells appeared singly in liquid culture. In contrast. TF-1a cells formed aggregates which increased markedly in size and in number upon TGFbeta1 treatment and showed a diminished TGFbeta-mediated growth inhibition. TF-1a, but not TF-1 cells, formed colonies in soft agar culture in the absence of any added growth factors, and developed the capacity to generate an invasive tumor(s) in nude mice. There was a constitutive activation of MAPK and MEK in TF-1a but not in TF-1 cells, which may be one of the mechanisms leading to factor-independent growth of TF-1a cells. Phenotypically, TF-1 cells were CD34+ /CD38+, whereas TF-1a cells were CD34+ /CD38-. This suggests that TF-1a may represent a less mature hematopoietic cell than TF-1. In conclusion, TF-1a is different from TF-1 in many important aspects which are associated with neoplastic transformation. The variant appears to be an excellent model for studying the process of progressive malignant transformation of myeloid cells and for studying signal pathways involved in the spontaneous and factor-induced growth of the cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9716013     DOI: 10.1016/s0145-2126(98)00073-3

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  5 in total

1.  Eliminating malignant contamination from therapeutic human spermatogonial stem cells.

Authors:  Serena L Dovey; Hanna Valli; Brian P Hermann; Meena Sukhwani; Julia Donohue; Carlos A Castro; Tianjiao Chu; Joseph S Sanfilippo; Kyle E Orwig
Journal:  J Clin Invest       Date:  2013-03-15       Impact factor: 14.808

2.  TGFbeta inhibits GM-CSF-induced phosphorylation of ERK and MEK in human myeloid leukaemia cell lines via inhibition of phosphatidylinositol 3-kinase (PI3-k).

Authors:  D E Montenegro; T Franklin; L C Moscinski; K S Zuckerman; X-T Hu
Journal:  Cell Prolif       Date:  2009-02       Impact factor: 6.831

3.  CRISPR/Cas9 knockouts reveal genetic interaction between strain-transcendent erythrocyte determinants of Plasmodium falciparum invasion.

Authors:  Usheer Kanjee; Christof Grüring; Mudit Chaand; Kai-Min Lin; Elizabeth Egan; Jale Manzo; Patrick L Jones; Tiffany Yu; Robert Barker; Michael P Weekes; Manoj T Duraisingh
Journal:  Proc Natl Acad Sci U S A       Date:  2017-10-19       Impact factor: 11.205

4.  Functional Characterization of D9, a Novel Deazaneplanocin A (DZNep) Analog, in Targeting Acute Myeloid Leukemia (AML).

Authors:  Xia Jiang; Cheryl Zi Hui Lim; Zhimei Li; Puay Leng Lee; Siti Maryam J M Yatim; Peiyong Guan; Juntao Li; Jianbiao Zhou; Jingxuan Pan; Wee-Joo Chng; Christina L L Chai; Qiang Yu
Journal:  PLoS One       Date:  2015-04-30       Impact factor: 3.240

5.  Inhibition of LIN28B impairs leukemia cell growth and metabolism in acute myeloid leukemia.

Authors:  Jianbiao Zhou; Chonglei Bi; Ying Qing Ching; Jing-Yuan Chooi; Xiao Lu; Jessie Yiying Quah; Sabrina Hui-Min Toh; Zit-Liang Chan; Tuan Zea Tan; Phyllis Sy Chong; Wee-Joo Chng
Journal:  J Hematol Oncol       Date:  2017-07-11       Impact factor: 17.388

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.